Fox Run Management’s Inovio Pharmaceuticals INO Stock Holding History

Fox Run Management’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,566	Closed	-$94K	–	605
2021 Q4	$94K	Buy	1,566 +641	+69%	+$51.4K	0.06%	419
2021 Q3	$79K	Buy	+925	New	+$92.8K	0.05%	441
2019 Q1	–	Sell	-1,205	Closed	-$58K	–	574
2018 Q4	$58K	Buy	+1,205	New	+$73.2K	0.03%	478
2016 Q3	–	Sell	-2,250	Closed	-$249K	–	575
2016 Q2	$249K	Buy	+2,250	New	+$273K	0.12%	359

Other funds holding INO

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fox Run Management's INO Position: Q1 2022 in Review

Fox Run Management sold out of Inovio Pharmaceuticals (INO) in Q1 2022, closing a stake of 1,566 shares — an estimated $94K sold.

Fox Run Management first reported a position in INO in Q2 2016 and held it in 4 quarters. The position peaked at $249K in Q2 2016. 198 funds tracked by Wall St. Rank hold INO as of Q1 2022.

Fox Run Management reported no remaining Inovio Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Fox Run Management sold 1,566 Inovio Pharmaceuticals shares in Q1 2022, an estimated $94K.
Fox Run Management first reported a position in Inovio Pharmaceuticals in Q2 2016 and held it in 4 quarters.
Fox Run Management's Inovio Pharmaceuticals position peaked at $249K in Q2 2016.
198 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2022.

Based on Fox Run Management's 13F filing for Q1 2022, filed 10 May 2022.